This inventor holds 6 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: Gw Research Limited, Universitë De Bordeaux, National Institute of Health and Medical Research. Active years: 2018-2026.
Location History:
- Barcelone, ES (2018)
- Barcelona, ES (2018 - 2023)
Company Filing History:
3 out of 49 
3 out of 226 
2 out of 1,853 
Years Active: 2018-2026
Title: Rafael Maldonado: Innovator in Cannabinoid Research
Introduction
Rafael Maldonado, an esteemed inventor based in Barcelona, Spain, boasts an impressive portfolio with a total of five patents. His pioneering work focuses primarily on the therapeutic applications of cannabinoids in treating neurological disorders, particularly autism spectrum disorder (ASD) and associated conditions.
Latest Patents
Maldonado's most recent patents demonstrate his commitment to advancing medical science. The first relates to the "Use of Cannabidiolic Acid in the Treatment of Autism Spectrum Disorder and Associated Disorders." This invention emphasizes the efficacy of cannabidiolic acid (CBDA) in improving cognitive dysfunctions in rodent models of ASD, Fragile X syndrome, Rett syndrome, and Angelman syndrome. Notably, Maldonado's formulation aims for a substantially pure CBDA, with a concentration exceeding 95% of the total extract.
His second significant patent addresses the "Use of Cannabidivarin in the Treatment of Autism Spectrum Disorder, Associated Disorders, and Schizophrenia." This invention highlights the advantages of cannabidivarin (CBDV) for similar neurological conditions, exhibiting substantial cognitive improvements in rodent models. The emphasis remains on achieving a highly purified extract or synthetically produced CBDV, tailored for therapeutic use.
Career Highlights
Throughout his career, Rafael Maldonado has collaborated with notable organizations such as GW Research Limited and Université de Bordeaux. His work in these institutions has played a crucial role in the development of cannabinoid-based treatments, aligning with his dedication to innovative research in medicine.
Collaborations
Maldonado's collaboration with proficient colleagues, including James Brodie and Marie Woolley-Roberts, has further enriched his research endeavors. Their collective expertise in pharmacology and biochemistry has contributed to the successful evolution of his inventive solutions in cannabinoid therapies.
Conclusion
In summary, Rafael Maldonado stands out as a significant figure in the realm of cannabinoid research, with groundbreaking patents on the treatment of autism spectrum disorder and related conditions. His work not only advances scientific knowledge but also holds promise for improving the lives of individuals affected by these challenging disorders.